Hasil untuk "math.QA"

Mike Gibson

PNGase F cleaves N-linked (asparagine-linked) oligosaccharides from glycoproteins. The enzyme deaminates asparagine to aspartic acid, leaving the oligosaccharides intact. Denaturation increases the rate of cleavage. Most native proteins can still be completely N-deglycosylated but incubation time must be increased. The enzyme will remain fully active under reaction conditions (37˚C) for at least 96 hours. PNGase F will not remove oligosaccharides containing Alpha-(1,3)-linked core fucose commonly found on plant glycoproteins; for this purpose, use peptide N-glycosidase A. There are a number of alternative enzymes which can be used to remove N-glycans, most especially the Endo F family of enzymes and Endo H. These enzymes cleave between the two N-acetylglucosamine residues in the core of the oligosaccharide, generating a truncated sugar molecule with one N-acetylglucosamine residue remaining on the asparagine. This leaves a charged sugar which can assist in keeping proteins in solution that precipitate after deglycosylation with PNGase F which removes the oligosaccharide intact. Endo F1cleaves high mannose and some hybrid type N-glycans. Endo F2will removes biantennary and high mannose (at a 40X reduced rate). Endo F3releases of triantennarry and fucosylated biantennary N-glycans. Endo Hremoves hybrid or high mannose glycans.

E Seravalli, A Houweling, M Van Gellekom et al.

Purpose:To independently validate patient‐specific quality assurance for IMRT and VMAT plans using the same set of treatment plans for all institutes.Methods:In February 2014 we devised a set of treatment plans: simple IMRT/VMAT plans; more complex IMRT/VMAT plans and a stereotactic VMAT plan, all 6MV for both Varian and Elekta linacs. In total we used 5 Varian and 8 Elekta plans. The plans were imported in the institute's treatment planning system for dose computation on the phantom of the audit team and the institute's phantom. Additionally, 10x10 cm2 fields were made and computed on both phantoms. Next, the audit team performed measurements using the audit equipment. So far, 18 audits have been performed and we expect to have concluded the audits by June 2015. The measurements were performed using an ionization chamber (PinPoint, PTW), Gafchromic film and a 2D ionization chamber array, all in an octagonal phantom (Octavius, PTW, see Figure). Differences between the measured and computed 2D dose distributions were investigated using a gamma analysis with a 5%/1mm criterion for the stereotactic treatment plan and 3%/3mm for the other plans. Additionally, the participating centres performed QA measurements of the same treatment plans according to their local protocol and equipment.Results:For the 10x10 field on the phantom, the first 18 audits showed differences with respect to the planning of −0.21 (range: −1.8; 2.2)%. See Table 1 for more results. The findings compared well with the QA measurement results reported by the institutions according to their local protocols.Conclusion:These preliminary results demonstrate that such a national QA audit is feasible. Importing and computing the prepared treatment plans in the planning systems in use in the country is achievable. The local QA systems provided similar results as found with the audit.

William R. Reinert, Virginia B. Patel, Norman H. Giles

qas qa

qas qa

QA Engineering Lead, USA, Komal Jasani

As virtual reality (VR) devices have expanded quickly, the arrival of applications that work on different platforms and devices has added greater complexity. Ensuring everything performs and looks the same on multiple platforms is a major challenge for QA teams. This study investigates effective lead QA strategies that can address these challenges within cross-platform VR development. Employing a qualitative case study approach, the research examines real-world practices of lead QA professionals managing multi-device testing processes. According to the research, you should begin testing quickly, change your tests, and cooperate closely with other departments. Many gamers complain about hardware, resource needs, and chatting issues, so tips are suggested to address them. The findings of this research help VR developers, managers, and others look for new practices and techniques to develop effective QA leadership in more advanced VR environments. This work has shown that better quality control and better user experiences can be achieved in cross-platform virtual reality.

César de Pablo-Sánchez, Ana González-Ledesma, Antonio Moreno-Sandoval et al.

Eduard H. Hovy, Ulf Hermjakob, Chin-Yew Lin

Nico Schlaefer, P. Gieselman, Guido Sautter

D. W. Gwyn

Bonnie Fossett, Barbara Desjardins